Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Eliem Therapeutics Inc (ELYM)

Eliem Therapeutics Inc (ELYM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 281,537
  • Shares Outstanding, K 27,724
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,120 K
  • 60-Month Beta -0.36
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.94
Trade ELYM with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.52 +302.98%
on 04/05/24
11.55 -12.08%
on 05/03/24
+7.38 (+266.61%)
since 04/03/24
3-Month
2.52 +302.98%
on 04/05/24
11.55 -12.08%
on 05/03/24
+7.50 (+283.21%)
since 02/02/24
52-Week
2.34 +333.97%
on 06/23/23
11.55 -12.08%
on 05/03/24
+6.73 (+196.93%)
since 05/03/23

Most Recent Stories

More News
Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

Initiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023 Sufficient...

ELYM : 10.15 (+21.04%)
Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022

SEATTLE and CAMBRIDGE, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company...

ELYM : 10.15 (+21.04%)
Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)

Topline data from the Phase 2a clinical trial are expected in the third quarter of 2022 Virtual investor event to be held in July 2022 SEATTLE and...

ELYM : 10.15 (+21.04%)
Eliem Therapeutics Reports First Quarter Financial and Business Highlights

SEATTLE and CAMBRIDGE, United Kingdom, May 16, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company...

ELYM : 10.15 (+21.04%)
Reata (RETA) Q1 Earnings Top, Omaveloxolone MAA Likely in Q4

Reata (RETA) reports a narrower-than-expected loss for the first quarter of 2022 while revenues miss estimates.

ABBV : 163.79 (+1.85%)
RETA : 172.36 (+0.02%)
LYEL : 2.36 (-1.67%)
ELYM : 10.15 (+21.04%)
Eliem Therapeutics, Inc. (ELYM) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Eliem Therapeutics, Inc. (ELYM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement...

ELYM : 10.15 (+21.04%)
Eliem Therapeutics Becomes Oversold (ELYM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

ELYM : 10.15 (+21.04%)
Eliem Therapeutics to Present at Stifel’s 2022 CNS Days

SEATTLE and CAMBRIDGE, United Kingdom, March 21, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company...

ELYM : 10.15 (+21.04%)
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business Highlights

 Completed dosing in Phase 2a clinical trial of ETX-810 in subjects with diabetic peripheral neuropathic pain; topline data to be presented in 1H 2022 ...

ELYM : 10.15 (+21.04%)
Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SEATTLE and CAMBRIDGE, United Kingdom, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company...

ELYM : 10.15 (+21.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based...

See More

Key Turning Points

3rd Resistance Point 14.82
2nd Resistance Point 13.19
1st Resistance Point 11.67
Last Price 10.15
1st Support Level 8.52
2nd Support Level 6.88
3rd Support Level 5.37

See More

52-Week High 11.55
Last Price 10.15
Fibonacci 61.8% 8.03
Fibonacci 50% 6.95
Fibonacci 38.2% 5.86
52-Week Low 2.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar